Versatope Therapeutics Inc
CAGE Code: 7TEE7
NCAGE Code: 7TEE7
Status: Active
Type: Commercial Supplier
Summary
Versatope Therapeutics Inc is an Active Commercial Supplier with the Cage Code 7TEE7.
Address
110 Canal St
Fl 4
Lowell MA 01852-4574
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Noble 2 Llc Loral Corp Loral Microwave Div U S Filter Corp Lookout Enterprises Inc Owl Stamp Company, Inc. Un, Vincent Je Learning/Hands On Learning J3 Learning Electro Circuits Inc Burkhart Trucking, Inc. R N T Technical Services Llc Raytheon Co Missile Systems Div Starflex, Inc. Nowlin Mark General Woodworking Inc Mammoth Fire Alarms Inc Amd Telemedicine Triple E Corporation Noir Materials Inc. Admiral Usa Inc
Frequently Asked Questions (FAQ) for CAGE 7TEE7
- What is CAGE Code 7TEE7?
- 7TEE7 is the unique identifier used by NATO Organizations to reference the physical entity known as Versatope Therapeutics Inc located at 110 Canal St, Fl 4, Lowell MA 01852-4574, United States.
- Who is CAGE Code 7TEE7?
- 7TEE7 refers to Versatope Therapeutics Inc located at 110 Canal St, Fl 4, Lowell MA 01852-4574, United States.
- Where is CAGE Code 7TEE7 Located?
- CAGE Code 7TEE7 is located in Lowell, MA, USA.
Contracting History for CAGE 7TEE7 Most Recent 25 Records
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 28 Sep 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,188,165.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Make An Award Under Hhs-Nih-Niaid-Baa2018
- 4 Sep 2019
- To Make An Award Under Hhs-Nih-Niaid-Baa2018
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,577,945.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 6 May 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,295,169.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 4 Dec 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $12,191,018.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 10 Sep 2021
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,295,169.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 22 Aug 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,188,165.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- Eo14042 - To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 25 Oct 2021
- Eo14042 - To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,295,169.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 12 Apr 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $9,102,819.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 6 Jun 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,793,945.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 3 Jul 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $9,102,819.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate Safety And Long-Term Immunogenicity With One And / Or Two Immunizations.
- 9 Jan 2020
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate Safety And Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,577,945.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 7 Mar 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,401,888.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 30 Aug 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $11,593,884.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 13 Sep 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $12,191,018.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 18 Nov 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,188,165.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 9 Dec 2021
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,295,169.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate Safety And Long-Term Immunogenicity With One And / Or Two Immunizations.
- 6 Feb 2020
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate Safety And Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,577,945.00
- Department Of Health And Human Services (Hhs)